0031-3998/08/6401-0056
PEDIATRIC RESEARCH
Copyright © 2008 International Pediatric Research Foundation, Inc.
Vol. 64, No. 1, 2008
Printed in U.S.A.
Chronic Hypoxia and Rat Lung Development: Analysis by
Morphometry and Directed Microarray
WILLIAM E. TRUOG, DONG XU, IKECHUKWU I. EKEKEZIE, SHERRY MABRY, MO REZAIEKHALIGH,
STAN SVOJANOVSKY, AND MICHAEL J. SOARES
Department of Pediatrics [W.E.T., D.X., I.I.E., S.M., M.R.], Section of Neonatology, University of Missouri-Kansas City School
of Medicine, Children’s Mercy Hospitals and Clinics, Kansas City, Missouri 64108; Department of Pathology and Laboratory
Medicine [M.J.S.], Institute of Maternal-Fetal Biology [W.E.T., M.J.S.], Department of Molecular and Integrative Physiology [S.S.],
University of Kansas School of Medicine, Kansas City, Kansas 66160
well as remodeling into vascular networks (4,5). The requirement of normal pulmonary vascularization for alveolarization
implies an interrelationship between capillary invasion and
alveolar septation (6). Factors that interfere with this process
may be sublethal in nature but result in long-term pulmonary
functional limitations (7).
Pulmonary vascular development proceeds under hypoxic
conditions in the fetus. Hypoxia is known to modulate the
expression of angiogenic factors and potentially to affect lung
microvascular development and lung morphogenesis (8).
However, the impact on microvascular alterations at the level
of these angiogenic factors by changes in oxygen tension has
not been thoroughly studied.
There are clinical implications to this issue. In the clinical
disorder, bronchopulmonary dysplasia (BPD), regional alveolar hypoxia likely develops in association with the distal
airway heterogeneous changes previously described (9).
Maldistribution of ventilation may develop especially during
the early phases of BPD when either no increase or when only
modest increases in FIO2 are administered. Alveolar hypoxia
then would develop in areas with very low ventilationperfusion ratios. Separate from the postnatal problems arising
in BPD, sustained altitude associated hypoxia has been associated with reduced gas exchange efficiency in otherwise
healthy term infants (10).
To evaluate the effects of alveolar hypoxia on developing lung,
we used the rat pup, whose saccular and alveolar stages of
development occur postnatally during the first 2 wks, compared
with prenatally in humans (2). We sought to relate morphometric
findings of microvascular and septal development to alterations
in lung expression of vasoactive substances.
ABSTRACT: It is unclear how sublethal hypoxia affects lung development. To investigate the effects of chronic hypoxia on postnatal
lung remodeling, we treated neonatal rats with FIO2 of 0.12 for 10 d
and analyzed lung development by morphometry and gene expression by DNA microarray. Our results showed the neonatal rats
exposed to hypoxia reduced body weight by 42% and wet lung
weight by 32% compared with the neonatal rats exposed to normoxia.
In the neonatal rats exposed to hypoxia, the radial alveolar counts
were decreased to 5.6 from 7.9 and the mean linear intercepts were
increased to 56.5 m from 38.2 m. In DNA microarray analysis,
approximately half of probed genes were unknown. Chronic hypoxia
significantly regulated expression of genes that are involved in
pathogenesis of pulmonary hypertension and postnatal lung remodeling. Chemokine ligand 12, jagged 2 were among those upregulated;
c-kit, ephrin A1, and Hif-2␣ were among those downregulated. The
altered expression of those genes was correlated with the lung
development and remodeling. (Pediatr Res 64: 56–62, 2008)
D
evelopment of the immature lung with a saccular morphology and limited gas exchange area to an architecturally mature lung with large internal surface area takes many
steps: thinning of alveolar septal walls, concomitant growth of
the capillary network, and extensive subdivision of gas exchange or acinar units. Alveolar septation apparently occurs as
secondary crests extend from primary alveolar walls and the
alveolar capillary network becomes more complex (1,2). Vascular development occurs by means of vasculogenesis, the
development of blood vessels from the differentiating of angioblasts in the mesoderm, and the more clinically relevant
process of angiogenesis, the sprouting of blood vessels from
existing vessels. Preacinar pulmonary arteries supplied by the
right heart grow with the airways into the intraacinar region
infused with the peripheral microvasculature that has arisen
there by means of vasculogenesis (3). Angiogenesis is orchestrated and mediated by interaction between and among protein
ligands and their cognate receptors to induce endothelial cell
proliferation, migration, differentiation, and organization as
METHODS
Animal exposure to oxygen. All experiments were conducted by protocols
approved by the Institutional Animal Care and Use Committee at the University of Kansas School of Medicine. Three treatment groups of pups were
created: pups from dams fed ad libitum and maintained in normoxia (room air,
n ⫽ 11), pups exposed to hypoxia (FIO2 ⫽ 0.12) from day 4 to day 14 of life
(n ⫽ 11), whose dams were fed ad libitum; and pups maintained in normoxia,
whose dams were pair-fed based on the amount of food consumed by their
Received September 25, 2007; accepted February 6, 2008.
Correspondence: William E. Truog, M.D., Department of Pediatrics, Section of
Neonatology, Children’s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City,
MO 64108; e-mail: wtruog@cmh.edu
This study was supported in part by the Hall Family Foundation, Kansas City,
Missouri for advancement of pediatric research and in part by the K-INBRE Bioinformatics Core, in part by NIH P20 RR016475 and in part by R-01HL70560 (W.E.T.).
Abbreviations: BPD, bronchopulmonary dysplasia; Lm, mean linear intercept; RAC, radial alveolar count; TLR, toll-like receptor
56
57
HYPOXIA AND LUNG DEVELOPMENT
hypoxia-exposed counterparts (n ⫽ 11). Normoxia and hypoxia dams in these
groups were rotated every 24 h during hypoxia exposure.
Total RNA preparation from tissue. Pups killed on day 10 of exposure (14
d of life) had lung tissue harvested. Total RNA was extracted with TRIzol
reagent from Invitrogen according to the manufacturer’s protocol. One microgram of total RNA was used for the first strand cDNA synthesis using
oligo d(T) primers according to the first strand cDNA synthesis kit protocol from
Invitrogen. Before cDNA synthesis, total RNA was treated with RNase-free
DNase I to eliminate any DNA contamination; nonreverse-transcription (without
adding reverse transcriptase in cDNA synthesis) samples were also included as
negative controls. The resulting cDNAs were then used for real-time PCR. The
primers used for Jagged 2 were, sense 5⬘-TGCACTGGTAGAGTACGTCCTTGT-3⬘ and antisense, 5⬘-AACAA CCAGTGGGCTCCGCTCAAT-3⬘; for
CXCL12: sense, 5⬘-GCCAACGTCAAACATCTGAA-3⬘, antisense: 5⬘TAATTTCGGGTCAATGCACA-3⬘. The real-time PCR was run with SYBR
green using two-step PCR protocol (95°C for 3 min; 95°C for 10 s, and 55°C, 45 s
for 40 cycles) with melting curve. The threshold cycle (Ct) was used to quantify
the sample mRNA levels with housekeeping gene -actin normalization.
Immunohistochemistry. Pups were killed at exposure day 0 (baseline) and
exposure days 3 and 10. Lungs were tracheally-perfused and fixed at 24 cm
H2O pressure for 24 h, with 4% buffered formaldehyde solution for histologic
studies. The lungs were then processed for histology by cutting into blocks at
right angles to the main bronchus. Tissue blocks were embedded in paraffin
and sectioned at a thickness of 5 m. Samples were mounted on positively
charged glass microscope slides and kept in a 60°C oven overnight, then
deparaffinized, and rehydrated. Staining was enhanced by steaming slides in
target retrieval solution (DAKO, Carpinteria, CA) for 20 min. After incubation
with blocking serum (DAKO, Carpinteria, CA) for 10 min, slides were incubated
with mouse anti-rat monoclonal PECAM-1 (CD31) antibody for 1 h (Serotec,
Kidlington, Oxford, UK). Sections were then immunohistochemically stained
using a modified avidin– biotin-peroxidase method (Vectastain ABC Elite Kit,
Vector Laboratories, Burlingame, CA). Antigenic sites were visualized by addition of the chromogen 3,3⬘ diaminobenzidine. Slides were counterstained with
Harris hematoxylin (Fisher HealthCare, Houston, TX). Negative control slides
were stained using the same procedure, omitting the primary antibody.
Western blotting analysis. Antibodies were purchased from Santa Cruz,
CA and used according to manufacturer’s instructions. Lungs were homogenized in RIPA buffer containing PBS, 0.1% SDS, 1% Igepal CA-630 (Sigma
Chemical Co., St. Louis, MO), and 0.5% sodium deoxycholate. At the time of
use, the following inhibitors were used in per gram tissue: 100 g/mL PMSF,
30 M Aprotinin (Sigma Chemical Co., St. Louis, MO), and 1 mM sodium
orthovanadate. The homogenate was centrifuged at 15,000g at 4°C for 20 min.
Protein was measured using bicinchoninic acid protein assay kit (Sigma
Chemical Co., St. Louis, MO) and then 60 g of protein/lane was applied on
a 10% Bis-Tris gel (Invitrogen, Carlsbad, CA). Protein was transferred to a
nitrocellulose membrane. The membrane was incubated for one hour at room
temperature with 5% nonfat milk in PBST (0.1% Tween-20 in PBS) to block
nonspecific binding. The membrane was immunoblotted with the primary antibody at 4°C overnight, followed by three 5-min washes with PBST and then
incubated with horseradish peroxidase-conjugated secondary antibody. Detection
was conducted by an enhanced chemiluminescent technique (Santa Cruz, CA).
The signals on autoradiogram were analyzed with Image software (Alpha Innotech, Sunnyvale, CA) and normalized by -actin in the same sample.
Morphometric analysis. Radial alveolar counts (RAC) were measured as
previously described (11,12), from the center of a bronchiole lined by
epithelium in one part of the wall. A perpendicular line was drawn using
image analysis to the nearest connective tissue septum or lung pleural surface,
and the number of alveoli cut by the line was counted. The radial alveolar
count was measured for every bronchiole on a slide and an average radial
alveolar count for the slide was calculated. All analyses were performed
without knowledge of the exposure group.
Mean linear intercepts (Lm) were measured using crossed hairlines of known
length (13). Fourteen consecutive parenchymal fields from each lung were
examined at ⫻200 magnification, on 5-m sections from the left lower lobe.
Using ANALYSIS Image Analysis (Soft Imaging Software, Lakewood, CO),
the volume density of PECAM-1 stained tissue (VV PECAM) per parenchyma was
determined in 14-d-old (day 10 of treatment) rat lungs. Parenchyma was defined
as alveolar ducts, alveoli, saccules, their air spaces, and septa. Fifteen fields per
animal were measured and averaged to obtain VV PECAM.
DNA microarray analysis. Experimental design of the microarray analysis
consists of three technical replicates for control and three replicates for the
hypoxia group. We used Affymetrix Rat 230 v.2.0 high density GeneChip威
and scanned with a GeneChip威 3000 High-resolution Scanner (Affymetrix,
Santa Clara, CA). This array represents about 31,000 probe sets for gene
expression level analysis of over 30,000 transcripts and variants that correspond to over 28,000 well-substantiated rat genes. The initial data captured by
Affymetrix GeneChip Operating Software (GCOS) resulted in a single raw
value related to each probe set based on the mean of differences between the
intensity of hybridization for each perfect match and the mismatch features for
a specific transcript. Experimental data set was exported via Data Transfer
Tool into the library data file by the GCOS software. Data Mining Tool
components were used to process the initial data quality control assessment
and to create sets of expressed probes. Total set of 31,099 probes for this
particular rat genome was divided into “present,” “marginal,” and “absent”
subsets based on calculated probe detection p-value. Probes present in at least
two microarray chips out of three in treatment vs. control were used for
evaluation of upregulated genes, whereas for downregulated genes probes
present in two of three control arrays facilitated the base for comparison.
Signal intensities for individual probe sets in the treatment and control
triplicates were subsequently compared statistically with significant differences at p ⱕ 0.05. GeneChip data sets from GCOS were transferred into text
file inputs for GeneSpring software (Agilent Technologies, Silicon Genetics,
Redwood City, CA), normalized per chip and gene and ranked according to
fold change for treatment vs. control signal intensities. GeneSpring software
was also used for graphical interpretation, gene annotation and gene ontologies for biologic processes, molecular functions, and cellular components.
Statistical analysis. The results are expressed as the mean ⫾ SEM of data
obtained from two or more experiments; or where appropriate, as mean ⫾ SD.
Paired or unpaired t tests were used as appropriate for the continuous data. A
value of p ⬍ 0.05 was considered significant.
RESULTS
Chronic hypoxia exposure lowers the body weight and
lung wet weight of the newborn rats. Newborn rats exposed
to hypoxia (FIO2 of 0.12) from days 4 to 14 showed a
significant body and lung wet weight reduction. During 10-d
treatment, body weight of the newborn rats breathing 12%
oxygen decreased to 15.7 g, 42% reduction, compared with that
of the newborn rats breathing room air (normoxia) with either ad
libitum (27 g) or limited fed (24 g) (n ⫽ 11, p ⬍ 0.002). The lung
wet weight of the newborn rats breathing 12% oxygen declined
to 0.28 g, 32% reduction, compared with that of the newborn rats
breathing room air (normoxia) with ad libitum (0.41 g) or limited
fed (0.41 g) (Table 1; n ⫽ 11, p ⬍ 0.001). Lung weight to body
weight ratios for each group are shown and demonstrate that
hypoxic exposure reduced overall body weight proportional to
lung weight (Table 1).
Chronic hypoxia exposure impairs alveolar formation of
the newborn rats. The newborn rats exposed to 10-d hypoxia
showed a significant RAC reduction. It was decreased to 5.6
from 7.9 or 7.8 compared with the newborn rats exposed to
normoxia with ad libitum or limited fed (Table 2; n ⫽ 11, p ⬍
0.002). The Lm was increased in the neonatal rats exposed to
hypoxia compared with the neonatal rats exposed to normoxia.
Lm was significantly increased to 56.5 m from 38.2 m after
10-d hypoxia exposure (Fig. 1; p ⬍ 0.05, n ⫽ 3– 4). No
changes were found after 3 d exposure to hypoxia. Lung
histology analyses showed a homogenous alveolar formation
Table 1. Chronic hypoxic exposure lowers the body weight and
lung wet weight of the newborn rats
Body weight Wet lung weight
(g), n ⫽ 11
(g), n ⫽ 7
Normoxia (ad libitum)
Normoxia (limited fed)
Hypoxia
27 ⫾ 2
24 ⫾ 2
15.7 ⫾ 2*
0.41 ⫾ 04
0.41 ⫾ 04
0.28 ⫾ 03*
Lung
weight/body
weight, n ⫽
0.015 ⫾ 0.002
0.017 ⫾ 0.003
0.016 ⫾ 0.032
The body weight, lung wet weight, and lung weight to body weight ratio of
the neonatal rats were assessed after 10-d exposure to normoxia (21% O2) or
hypoxia (12% O2).
* p ⬍ 0.001 compared with normoxia groups.
58
TRUOG ET AL.
Table 2. Chronic hypoxic exposure impairs alveolar formation of
the newborn rats
Radial alveolar
count (RAC)
Normoxia (ad libitum)
Normoxia (limited fed)
Hypoxia
7.9 ⫾ 1.0
7.8 ⫾ 0.9
5.6 ⫾ 1.3*
The radial alveolar count (RAC) was measured in the neonatal rat lungs
after 10-d exposure to normoxia (21% O2) or hypoxia (12% O2).
* p ⬍ 0.02 compared with normoxia groups.
in the newborn rats treated with normoxia with ad libitum or
limited fed (Fig. 2A). However, the alveolar formation was
reduced in the newborn rats treated with hypoxia and there
were fewer and larger alveoli in the hypoxia-treated lungs
compared with normoxia-treated lungs (Fig. 2B).
Chronic hypoxia exposure impairs pulmonary vascularization of the newborn rats. Pups exposed to 10-d hypoxia
showed a significant PECAM staining reduction. It was significantly decreased to 2.3% from 4.4% compared with the
newborn rats exposed to normoxia with ad libitum (Fig. 3; n ⫽
2– 4, p ⬍ 0.005).
Chronic hypoxia exposure alters gene expression in the
newborn rat lungs. Upregulated genes after chronic hypoxia
in the newborn rat lungs are summarized in Table 3 and
downregulated genes are summarized in Table 4. They represent only significantly upregulated or downregulated genes (t
test p-value ⬍0.005) with the fold change exceeding 2.0.
Because we have three technical replicates for each, treatment,
and control, the fold change was calculated from the average
Figure 1. Quantitative analysis of alveolar formation by the mean linear
intercept (Lm) measurement. Tissue sections from fixed neonatal rat lungs
exposed to either normoxia or hypoxia were measured for the mean linear
intercept under light microscope. Open squares: normoxia; closed squares:
hypoxia. *p ⬍ 0.05 compared with 10-d normoxia treatment group.
Figure 2. Chronic hypoxia exposure alters pulmonary morphology of the
newborn rats. Five micrometer sections from the neonatal rat lung tissues
were stained with hematoxylin and eosin (HE, 100⫻). (A) A representative
lung section from normoxic group; (B) a representative lung section from
hypoxic group.
Figure 3. Chronic hypoxia exposure impairs pulmonary vascularization of
the newborn rats. Lung tissue slides from the neonatal rats exposed to
normoxia or hyperoxia were staining with PECAM-1 and the staining signals
were quantified by ImageAnalysis software. Open squares: normoxia; closed
squares: hypoxia. *p ⬍ 0.005 compared with 10-d normoxia treatment group.
signals for treatment and control. Our selection is only on
genes present (detection p-value ⬍0.05) in at least two of the
three replicates. The genes are then clustered in different
subgroups based the gene annotation and gene ontology.
Among those significantly differentially expressed genes, approximately half of those genes were unknown. Chronic hypoxia exposure of the neonatal rat lungs significantly upregulated 66 genes with known functions (Table 3). These genes
participate in biologic process and molecular function in almost
every cellular compartment. Neurotrophic tyrosine kinase, receptor, type 2, chemokine (C-X-C motif) ligand 12, jagged 2 and
peroxiredoxin 2 were among those upregulated. The upregulation
of those genes suggested that chronic hypoxia increased cellular
metabolism, induced inflammation, reduced antioxidant capacity,
and interrupted lung development.
The 56 downregulated genes with known functions were
likely involved in pathogenesis of pulmonary hypertension,
angiogenesis, and changes in extracellular matrix (Table 4).
c-kit receptor tyrosine kinase, aldehyde dehydrogenase family
1, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide,
ephrin A1, and endothelial PAS domain protein 1 (Hif-2␣)
were among those downregulated, indicating that chronic
hypoxia induced pulmonary hypertension, decreased pulmonary angiogenesis, and induced pulmonary cell remodeling.
Expressions of toll-like receptors (TLR) genes TLR2,
TLR4, and nitric oxide synthase 1, 2, 3 genes were altered less
than 2-fold.
Validated gene expression related to pulmonary vascularization and alveolarization. We performed real-time PCR and
Western blotting analysis to validate CXCL12, jagged2,
Hif2␣, and c-Kit expression in the neonatal rat lungs exposed
to hypoxia for 0, 3, and 10 d. CXCL12 gene expression was
increased by 1.8-fold after 10-d hypoxia exposure compared
with normoxia exposure (Fig. 4A). Jagged 2 gene expression
was increased by 1.8 and 2.2-fold after 3- and 10-d hypoxia
exposure compared with normoxia exposure (Fig. 4B). Increased CXCL12 and Jagged 2 gene expression after hypoxia
exposure was negatively correlated with the development of the
neonatal lungs. Western blotting showed Hif-2␣ was decreased
by 2-fold after 10 d hypoxia exposure (Fig. 4C and E) and c-Kit
59
HYPOXIA AND LUNG DEVELOPMENT
Table 3. Upregulated genes in the newborn rat lungs after 10-d chronic hypoxic exposure
Gene
Metabolism
Chitinase, acidic
Solute carrier family 1
Rhesus blood group-associated A glycoprotein
Solute carrier family 4, member 1
Intersectin 1
Solute carrier family 4, member 1
Transferrin receptor
Aminolevulinic acid synthase 2
Peptidoglycan recognition protein
Secretoglobin, family 3A, member 1
Alpha-2u globulin PGCL4
Organic cation transporter OCTN1
Arachidonate 12-lipoxygenase
Cytosolic cysteine dioxygenase 1
S-adenosylmethionine decarboxylase 1
Aldose reductase-like protein
Transferrin
Metallothionein
Monocarboxylate transporter
Coagulation factor XIIIa
Adenylate kinase 4
RNA binding motif protein 14
Lipase, hormone sensitive
Chitinase 3-like 1 (cartilage glycoprotein-39)
Apobec-1 complementation factor
Solute carrier family 28, member 2
Peptidyl arginine deiminase, type 4
Inhibitor of DNA binding 4
UDP-glucuronosyltransferase
Fatty acid elongase 2
Asparagine synthetase
Extracellular matrix
Matrix metalloproteinase 9
Skeletal/cell adhesion
Lectin, galactose binding, soluble 5
Embigin
Troponin T2
Growth
Erythroid differentiation gene 1
Resistin-like alpha
Follistatin
Neuritin
Schlafen 4
Neurturin
Plasticity related gene 1
Cell division cycle 25B
EGL nine homolog 3 (C. elegans)
Inflammation
Tumor necrosis factor receptor 1b
S100 calcium-binding protein A8
S100 calcium-binding protein A9
Interferon-gamma inducible gene, Puma-g
Cathelicidin
Chemokine (C-X-C motif) ligand 12
Interleukin 1 receptor, type II
Signaling
Regulated endocrine-specific protein 18
Delta-like homolog (Drosophila)
CD52 antigen
Neurotrophic tyrosine kinase, receptor, type 2
Arg/Abl-interacting protein ArgBP2
WNT1 inducible signaling pathway protein 2
Purinergic receptor P2Y, G-protein coupled 2
Calcium binding protein 1
Arginine vasopressin receptor 1A
Jagged 2
Defense response
Heat shock 70kD protein 1A
Synuclein, alpha
Peroxiredoxin 2
Transcription
Activating transcription factor 3
DNA-damage inducible transcript 3
Common number
Accession change
Fold value
p
Chia
Slc1a6
Rhag
Slc4a1
Itsn
Slc4a1
Tfrc
Alas2
Pglyrp
Scgb3a1
Obp3
Octn1
Alox12
Cdo1
Amd1
LOC286921
Tf
Mt1a
Mct3
F13a
Ak4
Rbm14
Lipe
Chi3l1
Acf
Slc28a2
Pdi4
Idb4
LOC286989
rELO2
Asns
AI639227
NM_032065
NM_023022
BE113640
BF406692
AY030082
BF417032
NM_013197
NM_053373
AI011836
J00738
NM_022270
NM_031010
NM_052809
NM_031011
AI233740
AA945178
AF411318
NM_030834
BM388525
AA891949
BF284573
NM_012859
AA945643
NM_133400
NM_031664
AB008803
AI412150
U27518
BF396857
U07202
9.1
7.9
7.6
6.4
4.3
3.8
3.8
3.8
3.5
3.3
3.2
3.0
3.0
2.8
2.8
2.7
2.6
2.5
2.5
2.4
2.4
2.4
2.3
2.3
2.2
2.2
2.2
2.2
2.1
2.1
2.0
0.005
0.000
0.047
0.001
0.001
0.012
0.003
0.000
0.003
0.010
0.036
0.002
0.001
0.014
0.031
0.000
0.003
0.016
0.001
0.000
0.034
0.009
0.004
0.003
0.031
0.000
0.045
0.006
0.004
0.003
0.026
Mmp9
NM_031055
3.6
0.022
Lgals5
Emb
Tnnt2
NM_012976
NM_053719
NM_012676
2.9
2.7
2.4
0.007
0.020
0.006
Edag1
Retnla
Fst
Nrn
Slfn4
Nrtn
Prg1
Cdc25b
Egln3
NM_133294
NM_053333
NM_012561
NM_053346
NM_053687
AI598581
AW526088
NM_133572
NM_019371
3.8
3.5
3.4
3.4
3.2
3.0
2.7
2.3
2.0
0.001
0.013
0.045
0.002
0.002
0.025
0.010
0.001
0.010
Tnfrsf1b
S100a8
S100a9
Pumag
CRAMP
Cxcl12
Il1r2
BM390522
NM_053822
NM_053587
BI296811
AA998531
BF283398
NM_053953
4.5
4.2
3.7
2.9
2.6
2.1
2.1
0.006
0.005
0.005
0.010
0.034
0.001
0.026
Resp18
Dlk1
Cd52
Ntrk2
Argbp2
Wisp2
P2ry2
Cabp1
Avpr1a
Jag2
NM_019278
NM_053744
NM_053983
M55292
NM_053770
NM_031590
NM_017255
AJ315761
NM_053019
BI274746
16.7
5.5
4.8
4.7
3
2.7
2.4
2.3
2.3
2.1
0.004
0.046
0.021
0.023
0.014
0.027
0.024
0.012
0.026
0.013
Hspa1a
Snca
Prdx2
BI278231
NM_019169
NM_017169
2.5
2.3
2.1
0.040
0.025
0.013
Atf3
Ddit3
NM_012912
NM_024134
2.3
2.2
0.001
0.029
Total RNA from the neonatal rat lungs exposed to normoxia or hypoxia for 10 d was used for gene expression analysis using rat Affymatrix gene chips.
Triplicate samples were analyzed from each group. p-value was calculated by t test.
60
TRUOG ET AL.
Table 4. Downregulated genes in the newborn rat lungs after 10-d chronic hypoxic exposure
Gene
Metabolism
Aldehyde dehydrogenase family 1
NAD-dependent 15-hydroxyprostaglandin dehydrogenase
3-alpha-hydroxysteroid dehydrogenase
Eosinophil cationic protein
Dopa decarboxylase
Solute carrier family 28
P-glycoprotein/multidrug resistance 1
Rab3B protein
ATP-binding cassette, sub-family B (MDR/TAP)
Monoamine oxidase B
Flavin containing monooxygenase 4
Pyruvate dehydrogenase kinase 2
3-hydroxy-3-methylglutaryl-coenzyme A synthase 2
Casein kinase II, alpha 1 polypeptide
Chloride channel 7
Acyl-coenzyme A oxidase 2, branched chain
Sulfatase FP
Extracellular matrix
Lumican
Vitronectin
Bone morphogenetic protein 1 (procollagen C-proetinase)
Matrix metalloproteinase 14, membrane-inserted
Procollagen, type XII, alpha 1
Actin alpha cardiac 1
Skeletal/cell adhesion
Claudin 11
Opioid-binding protein/cell adhesion molecule-like
Nuclear pore membrane glycoprotein 210
CD38 antigen
Growth
Bone specific CMF608
Niban protein
Protocadherin alpha 13
Insulin-like growth factor-binding protein 5
Cyclin dependent kinase inhibitor 2C
Inflammation
Interleukin 1 alpha
T-cell receptor gamma chain
T-cell receptor beta chain
Signaling
Vasoactive intestinal peptide receptor 1
Bradykinin receptor B2
G protein-coupled receptor 105
Carcinoembryonic antigen-related cell adhesion molecule 1
Natriuretic peptide receptor 3
c-kit receptor tyrosine kinase
Neurotensin receptor 2
Adrenomedullin
Glial cell line-derived neurotrophic factor family receptor alpha 2
Regulator of G-protein signaling 7
Thyroid stimulating hormone, receptor
Adrenomedullin receptor
Phosphatidylinositol 3-kinase, catalytic, alpha polypeptide
Angiopoietin-like 2
Ephrin A1
Calcitonin receptor-like
RAS guanyl releasing protein 1
Endothelial PAS domain protein 1
Transcription
Period 1
Zinc finger protein 354C
Transcription factor E2a
Common number
Accession change
Fold value
p
Aldh1a4
Hpgd
LOC191574
Loc192264
Ddc
Slc28a3
Pgy1
Rab3b
Abcb1a
Maob
Fmo4
Pdk2
Hmgcs2
Csnk2a1
Clcn7
Acox2
LOC171396
M23995
AA848820
M61937
D88586
BI296559
NM_080908
AY082609
NM_031091
AF257746
NM_013198
BI293319
AF237719
M33648
BF555171
NM_031568
X95189
NM_134378
⫺9.6
⫺5.1
⫺4.0
⫺3.4
⫺3.4
⫺3.3
⫺3.2
⫺3.0
⫺2.7
⫺2.4
⫺2.3
⫺2.1
⫺2.1
⫺2.1
⫺2.1
⫺2.1
⫺2.0
0.035
0.004
0.009
0.002
0.001
0.009
0.014
0.012
0.012
0.000
0.009
0.005
0.027
0.003
0.049
0.008
0.003
Lum
Vtn
Bmp1
Mmp14
Col12a1
Actc1
NM_031050
NM_019156
AB012139
X83537
U57361
BF525047
⫺2.4
⫺2.3
⫺2.1
⫺2.1
⫺2.1
⫺2.1
0.004
0.016
0.018
0.004
0.022
0.016
Cldn11
Opcml
Pom210
Cd38
NM_053457
NM_053848
NM_053322
D30795
⫺3.2
⫺2.3
⫺2.3
⫺2.1
0.018
0.011
0.002
0.002
LOC310448
Niban
Pcdha13
Igfbp5
Cdkn2c
BF543355
NM_022242
BG663483
BF399783
NM_131902
⫺2.7
⫺2.3
⫺2.1
⫺2.0
⫺2.0
0.004
0.016
0.000
0.006
0.010
Il1a
Tcrg
Tcrb
AJ245643
Z27087
AW919577
⫺2.2
⫺2.1
⫺2.0
0.008
0.003
0.010
Vipr1
Bdkrb2
Gpr105
Ceacam1
Npr3
Kit
Ntsr2
Adm
Gfra2
Rgs7
Tshr
Admr
Pik3ca
Angptl2
Efna1
Calcrl
Rasgrp1
Epas1
NM_012685
BF408558
U76206
NM_031755
AI574783
NM_022264
U18772
NM_012715
BE114004
NM_019343
NM_012888
NM_053302
AA964375
NM_133569
NM_053599
NM_012717
AF081196
NM_023090
⫺5.1
⫺4.1
⫺3.8
⫺3.7
⫺3.4
⫺3.0
⫺3.0
⫺2.6
⫺2.5
⫺2.5
⫺2.5
⫺2.4
⫺2.3
⫺2.1
⫺2.1
⫺2.0
⫺2.0
⫺2.0
0.006
0.007
0.001
0.018
0.038
0.003
0.002
0.013
0.021
0.000
0.004
0.007
0.002
0.011
0.005
0.049
0.013
0.014
Per1
Znf354c
Tcfe2a
BI279017
NM_023988
NM_133524
⫺4.5
⫺2.2
⫺2.1
0.015
0.011
0.038
Total RNA from the neonatal rat lungs exposed to normoxia or hypoxia for 10 d was used for gene expression analysis using rat Affymatrix gene chips.
Triplicate samples were analyzed from each group. p-value was calculated by t test.
HYPOXIA AND LUNG DEVELOPMENT
61
Figure 4. Validation of gene expression by quantitative PCR and Western blotting analysis. (A) and (B), CXCL12 and Jagged 2 gene expression in the neonatal
rat lungs exposed to either normoxia or hypoxia for 0, 3, and 10 d was performed by quantitative real-time PCR. Open square: normoxia; closed square: hypoxia.
(C) and (D), Hif-2␣ and C-Kit protein expression in the neonatal rat lungs exposed to either normoxia or hypoxia for 0, 3, and 10 d was analyzed by Western
blotting. (E), Western blotting analysis of Hif2␣ expression; N: normoxia; H: hypoxia. (F), Western blotting analysis of c-Kit expression; N: normoxia; H:
hypoxia; Open squares: normoxia; closed squares: hypoxia.
was decreased by 2-fold after 10-d hypoxia exposure (Fig. 4D
and F), which were consistent with the gene expression data from
Affymatrix DNA microarray. The increased expression of
CXCL12 and jagged 2 and decreased expression of Hif-2␣ and
c-Kit were correlated with the reduction of alveolar formation
during chronic hypoxia exposure.
DISCUSSION
In this study, we analyzed differential gene expression and
distal lung development after FIO2 of 0.12 exposure from day
4 to day 14. Hypoxia in the dose and duration used impaired
alveolar formation and reduced body weight and lung wet
weight during the secondary septation period. Hypoxic exposure increased gene expression of Notch signaling such as
jagged 2, and antioxidants such as heat shock protein 70 and
peroxiredoxin 2; decreased gene expression of ephrin A1 and
Hif-2␣ that are implicated in vascularization. Real-time PCR
and Western blotting confirmed that downregulation of Hif-2␣
and c-Kit, and upregulation of CXCL12 and jagged 2 are
correlated with impairment of alveolar formation after chronic
hypoxia in the neonatal rat lungs.
Chronic hypoxia can impair pulmonary vascularization and
alveolar formation in neonatal rats and humans (14,15). Alveolar hypoxia in this model reduced pulmonary vessel density, RAC and increased mean Lm. The pups demonstrated
fewer and larger alveoli. In addition, it significantly impeded
pulmonary vascularization as assessed by decreased vessel
density. Our findings suggest that there was diminished secondary septation. Lung development in the first 2 wks of life
is largely dependent on secondary septation (2,16,17). However, it is unclear how hypoxia affects the secondary septation.
To help clarify this process, we performed DNA array analysis
and probed more than 2800 genes. Among those significantly
differentially expressed genes, approximately half of those
genes were unknown. Chronic hypoxia in the neonatal rat lung
significantly upregulated and downregulated genes related to
pathogenesis of pulmonary hypertension and vascularization.
For example, jagged 2, a ligand of Notch receptors, was
significantly increased during hypoxia exposure, suggesting
that Notch signaling pathway may be dysregulated in the
newborn rats exposed to chronic hypoxia. The Notch signaling
pathway plays an important role in the regulation of arterialvenous differentiation. Jagged 2 is expressed in endothelial
cells in developing lungs (18,19). The Notch ligand negatively
regulated vascularization during development and interruption
of Notch signaling increases number of lung buds and branching morphogenesis, although the exact role of Jagged 2 in the
developing lungs has not been clearly defined (20 –22).
CXCL12 (also known as stromal cell-derived factor-1) and its
receptor, CXCR4, play important roles in ischemic tissue
repair, progenitor cell mobilization, and neovascularization
during hypoxia exposure (23,24). We found that CXCL12 was
significantly elevated in the hypoxia-exposed lungs, which
indicated that CXCL12 might participate in pulmonary remodeling after hypoxia. The downregulation of c-Kit, a transmembrane tyrosine kinase receptor for stem-cell factor, may
reflect the decreasing mobilization of c-Kit positive cells from
the bone marrow to lung after prolonged hypoxia. Recent data
have suggested that c-kit positive cells could differentiate into
endothelial cells and could be involved in the hypoxia-induced
remodeled pulmonary artery vessel wall (25).
The finding of decreased Hif 2␣ expression was unexpected, but it has been reported that chronic hypoxia could
reduce gene expression that Hif regulates (26). Chronic hypoxia also altered gene expression in inflammation, oxidative
stress, and cell survival pathways, suggesting that multiple
factors and pathways are involved in postnatal lung remodeling during chronic hypoxia. Genes participating in the regulation of TLR were altered by ⬍2-fold. This finding was of
importance, as relative TLR4 deficiency has been shown to
induce susceptibility to a different model of lung injury (27).
We used a conservative cutoff of 2-fold gene alteration as a
criterion in the gene expression analysis and examined one
relatively late time point, hypoxia for 10 d. Additional gene
62
TRUOG ET AL.
upregulation or downregulation might have been found if we
have looked at the early time points such as hypoxia for 3 d.
Several features of the model used in these experiments
need to be discussed. Animals were exposed to FIO2 ⫽ 0.12
beginning on day 4 and continuing to day 14 of life. We chose
this model after pilot work with exposure to FIO2 ⫽ 0.10
resulted in unacceptably high mortality at and beyond 7 d of
exposure. Also, infants born at an altitude at which the FIO2
is approximately 0.12 (28) demonstrate impaired gas exchange (10). With FIO2 ⫽ 0.12 there were no unplanned
deaths of the exposure pups. We waited 4 d after birth to
initiate hypoxic exposure to mimic the contemporary clinical
course of BPD. There is often a “honeymoon” of up to one to
2 wks during which supplemental FIO2 needs and ventilatory
support are minimal. Our findings, obtained after a short
waiting period, demonstrate that sublethal alveolar hypoxia
still profoundly disrupts pulmonary development, and that
histologically, 3 d exposure is insufficient to produce these
changes. There are obvious limitations in comparing carefully
controlled administration of O2 and resultant perturbations in
lung development conducted on small mammal species to human
studies, but this brief period of normoxia followed by 10 d
breathing FIO2 of 0.12 was associated with histopathological and
transcriptive changes. We cannot speculate as to whether hypoxia
beginning at day 0, or alternatively, waiting until day 7 would
have exacerbated or minimized these findings.
There are several unique features to the study. To our
knowledge, ours is the first report using the rat-specific wide
array gene chip analysis for identifying rat lung gene expression profiles following alveolar hypoxic exposure. Several
previously uncharacterized gene expression patterns were
identified and potentially offer important therapeutic targets.
We sought to identify correlations between alveolar and microvascular abnormal development and up- or downregulation
of key genes in the rat lung known or suspected to be
associated with vascular/airway development. Other methodological factors of note included the use of a concurrent limited
feeding group to minimize, but likely not eliminate, the effect of
reduced nutritional intake by the rat pups during their hypoxic
exposure. Use of a pair fed normoxia comparison group increases
the likelihood that the pulmonary findings in the chronic hypoxia
group were caused directly by the effects of alveolar hypoxia and
not by secondary effects of nutrient intake.
In summary, we showed that chronic hypoxia interrupted
lung development, likely inducing permanent structural alterations. The corresponding altered gene expression pattern
indicates that multiple pathways were involved.
REFERENCES
1. Burri PH 1997 Structural aspects of pre- and postnatal development and growth of
the lung. In: McDonald JA (ed) Growth and Development of the Lung. Marcel
Dekker, Inc., New York, pp 1–35
2. Burri PH 1984 Fetal and postnatal development of the lung. Annu Rev Physiol
46:617– 628
3. Risau W 1991 Vasculogenesis, angiogenesis and endothelial cell differentiation
during embryonic development. In: Feinberg RN, Sherer GK, Auerbach R (eds) The
Development of the Vascular System. Karger, Biomed Basel 14: pp 58 – 68
4. Gale NW, Yancopoulos GD 1999 Growth factors acting via endothelial cell-specific
receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13:1055–1066
5. DeMello DE, Reid LM 1991 Pre- and postnatal development of the pulmonary
circulation. In: Chernick V, Mellins RB (eds) Basic Mechanisms of Pediatric
Respiratory Disease: Cellular and Integrative. Decker, Philadelphia, pp 6 –54
6. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, Abman SH 2000
Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J
Physiol Lung Cell Mol Physiol 279:L600 –L607
7. Stenmark KR, Abman SH 2005 Lung vascular development: implications for
the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol 67:623661
8. Semenza GL 2005 Pulmonary vascular responses to chronic hypoxia mediated by
hypoxia-inducible factor 1. Proc Am Thorac Soc 2:68 –70
9. Thibeault DW, Truog WE, Ekekezie I 2003 Acinar arterial changes with chronic
lung disease of prematurity in the surfactant era. Pediatr Pulmonol 36:482489
10. Niermeyer S, Yang P, Shanmina, Drolkar, Zhuang J, Moore LG 1995 Arterial
oxygen saturation in Tibetan and Han infants born in Lhasa, Tibet. N Eng J Med
333:1248 –1252
11. Cooney TP, Thurlbeck WM 1982 The radial alveolar count method of Emery and
Mithal: a reappraisal 1—postnatal lung growth. Thorax 37:580 –583
12. Emery JL, Mithal A 1960 The number of alveoli in the terminal respiratory unit of
man during intrauterine life and childhood. Arch Dis Child 35:544 –547
13. Dunnill MS 1962 Quantitative methods in the study of pulmonary pathology. Thorax
17:320 –328
14. Deruelle P, Balasubramaniam V, Kunig AM, Seedorf GJ, Markham NE, Abman SH
2006 BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right
ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic
hypoxia in neonatal rats. Biol Neonate 90:135–144
15. Chess PR, D’Angio CT, Pryhuber GS, Maniscalco WM 2006 Pathogenesis of
bronchopulmonary dysplasia. Semin Perinatol 30:171–178
16. Thibeault DW, Mabry SM, Norberg M, Truog WE, Ekekezie II 2004 Lung
microvascular adaptation in infants with chronic lung disease. Biol Neonate
85:273–282
17. Olsen SL, Thibeault DW, Mabry SM, Norberg M, Truog WE 2002 Platelet endothelial cell adhesion molecule-1 and capillary loading in premature infants with and
without chronic lung disease. Pediatr Pulmonol 33:255–262
18. Taichman DB, Loomes KM, Schachtner SK, Guttentag S, Vu C, Williams P, Oakey
RJ, Baldwin HS 2002 Notch1 and Jagged1 expression by the developing pulmonary
vasculature. Dev Dyn 225:166 –175
19. Iso T, Hamamori Y, Kedes L 2003 Notch signaling in vascular development.
Arterioscler Thromb Vasc Biol 23:543–553
20. Suchting S, Freitas C, le Noble F, Benedito R, Breant C, Duarte A, Eichmann A
2007 The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci USA 104:3225–3230
21. Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos
GD, Wiegand SJ 2007 Delta-like ligand 4 (Dll4) is induced by VEGF as a
negative regulator of angiogenic sprouting. Proc Natl Acad Sci USA 104:3219 –
3224
22. Kong Y, Glickman J, Subramaniam M, Shahsafaei A, Allamneni KP, Aster JC, Sklar
J, Sunday ME 2004 Functional diversity of notch family genes in fetal lung
development. Am J Physiol Lung Cell Mol Physiol 286:L1075–L1083
23. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME,
Capla JM, Galiano RD, Levine JP, Gurtner GC 2004 Progenitor cell trafficking is
regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med
10:858 – 864
24. Lima e Silva R, Shen J, Hackett SF, Kachi S, Akiyama H, Kiuchi K, Yokoi K, Hatara
MC, Lauer T, Aslam S, Gong YY, Xiao WH, Khu NH, Thut C, Campochiaro PA
2007 The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several
types of ocular neovascularization. FASEB J 21:3219 –3230
25. Davie NJ, Crossno JT Jr, Frid MG, Hofmeister SE, Reeves JT, Hyde DM, Carpenter
TC, Brunetti JA, McNiece IK, Stenmark KR 2004 Hypoxia-induced pulmonary
artery adventitial remodeling and neovascularization: contribution of progenitor
cells. Am J Physiol Lung Cell Mol Physiol 286:L668 –L678
26. Grover TR, Asikainen TM, Kinsella JP, Abman SH, White CW 2007 Hypoxiainducible factors HIF-1␣ and HIF-2 ␣ are decreased in an experimental model of
severe respiratory distress syndrome in preterm lambs. Am J Physiol Lung Cell Mol
Physiol 292:L1345–L1351
27. Zhang X, Shan PBlob, Qureshi S, Homer R, Medzhitov R, Noble PW, Lee PJ 2005
Cutting edge: TLR4 deficiency confers susceptibility to lethal oxidant lung injury.
J Immunol 175:4834 – 4838
28. Erzurum SC, Ghosh S, Janocha AJ, Xu W, Bauer S, Bryan NS, Tejero J, Hemann
C, Hille R, Stuehr DJ, Feelisch M, Beall CM 2007 Higher blood flow and circulating
NO products offset high-altitude hypoxia among Tibetans. Proc Natl Acad Sci USA
104:17593–17598